BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
|
9 Months Ended |
Sep. 30, 2026 |
|---|
| Accounting Policies [Abstract] |
|
| SCHEDULE OF DISAGGREGATED REVENUE |
For
the three and nine months ended September 30, 2026 and 2025, the Company had the following disaggregated revenue:
SCHEDULE OF DISAGGREGATED REVENUE
| | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| | |
2026 | | |
% | | |
2025 | | |
% | | |
2026 | | |
% | | |
2025 | | |
% | |
| Telehealth subscription revenue | |
$ | 27,714,009 | | |
| 62 | % | |
$ | 27,748,440 | | |
| 58 | % | |
$ | 87,379,901 | | |
| 62 | % | |
$ | 86,127,426 | | |
| 59 | % |
| Telehealth product revenue | |
| 16,828,707 | | |
| 38 | % | |
| 19,979,502 | | |
| 42 | % | |
| 54,586,577 | | |
| 38 | % | |
| 60,734,271 | | |
| 41 | % |
| Telehealth service fee revenue(1) | |
| 82,370 | | |
| 0 | % | |
| — | | |
| — | | |
| 82,370 | | |
| 0 | % | |
| — | | |
| — | |
| Total revenues, net | |
$ | 44,625,086 | | |
| 100 | % | |
$ | 47,727,942 | | |
| 100 | % | |
$ | 142,048,848 | | |
| 100 | % | |
$ | 146,861,697 | | |
| 100 | % |
| (1) | Telehealth
service fee revenue primarily relates to data reporting fees charged by the Company in connection
with the fulfillment of orders for the Company’s pharmaceutical supply agreements. |
|
| SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY |
The
following table summarizes deferred revenue activities for the periods presented:
SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| |
|
Three
Months Ended September 30, |
|
|
Nine
Months Ended September 30, |
|
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| Beginning
of period |
|
$ |
10,791,221 |
|
|
$ |
14,282,482 |
|
|
$ |
10,573,442 |
|
|
$ |
16,824,629 |
|
| Additions |
|
|
43,120,124 |
|
|
|
43,908,222 |
|
|
|
139,474,684 |
|
|
|
139,406,075 |
|
| Revenue
recognized |
|
|
(43,477,838 |
) |
|
|
(46,230,813 |
) |
|
|
(139,614,619 |
) |
|
|
(144,270,813 |
) |
| End
of period |
|
$ |
10,433,507 |
|
|
$ |
11,959,891 |
|
|
$ |
10,433,507 |
|
|
$ |
11,959,891 |
|
|
| SUMMARY OF INVENTORY |
As
of September 30, 2026 and December 31, 2025, the Company’s inventory consisted of the following:
SUMMARY OF INVENTORY
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| Finished goods | |
$ | 9,431,784 | | |
$ | 2,071,988 | |
| Raw materials and packaging components | |
| 1,070,209 | | |
| 854,980 | |
| Inventory reserve | |
| (153,392 | ) | |
| (153,392 | ) |
| Total inventory, net | |
$ | 10,348,601 | | |
$ | 2,773,576 | |
|
| SUMMARY OF DEPRECIABLE ASSETS |
As
of September 30, 2026 and December 31, 2025, the Company has the following amounts related to depreciable assets:
SUMMARY OF DEPRECIABLE ASSETS
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| Furniture, fixtures and office equipment | |
$ | 3,393,136 | | |
$ | 3,272,857 | |
| Computers | |
| 1,102,481 | | |
| 879,686 | |
| Total equipment, at cost | |
| 4,495,617 | | |
| 4,152,543 | |
| Accumulated depreciation | |
| (2,590,463 | ) | |
| (1,707,826 | ) |
| Total equipment, net | |
$ | 1,905,154 | | |
$ | 2,444,717 | |
|